# Notch Inhibitor in Advanced Cancer

> **NCT01158404** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 35 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** LY900009 - Dose Escalation Phase (Part A)
- **DRUG:** LY900009 - Dose Confirmation Phase (Part B)

## Key facts

- **NCT ID:** NCT01158404
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158404, "Notch Inhibitor in Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01158404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*